GLPwatch
Open Label, 4 Week Study of ITCA 650 in Adults With Type 2 Diabetes
NCT01798264 · Completed
Last updated 2026-05-28This clinical trial tested the safety of ITCA 650, a new diabetes medication, in adults with type 2 diabetes over a 4-week period.
Status Completed The study has finished.
Phase Phase 1 Checks safety and dosing in a small group.
Type Interventional (clinical trial)
Design Randomized, open-label (no blinding) treatment study
Participants 44 people
Who can join Ages 30–70 · all sexes
Timeline Started 2009-02 · est. completion 2009-05
Where 3 sites · United States
What this study is testing ClinicalTrials.gov NCT01798264 ↗
Description as written by the study sponsor.
evaluate the safety and tolerability of ITCA 650 in subjects with type 2 diabetes mellitus.
Treatments tested
- ITCA 650 (exenatide in DUROS) Drug
| Main thing measured | Number of Subjects With Study Drug-Related Adverse Events |
|---|---|
| Sponsor | Intarcia Therapeutics |
| Conditions studied | Type 2 Diabetes |
| GLP-1 drugs | — |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01798264 ↗